Kraj: Unia Europejska
Język: angielski
Źródło: EMA (European Medicines Agency)
adalimumab
Abbott Laboratories Ltd.
L04AA17
adalimumab
Immunosuppressants
Spondylitis, Ankylosing; Arthritis, Rheumatoid; Arthritis, Psoriatic; Crohn Disease
Rheumatoid arthritisTrudexa in combination with methotrexate, is indicated for:the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.Trudexa can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.Trudexa has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Psoriatic arthritisTrudexa is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.Ankylosing spondylitisTrudexa is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.Crohn's diseaseTrudexa is indicated for treatment of severe, active Crohn's disease, in patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. For induction treatment, Trudexa should be given in combination with cortiocosteroids. Trudexa can be given as monotherapy in case of intolerance to corticosteroids or when continued treatment with corticosteroids is inappropriate (see section 4.2).
Revision: 8
Withdrawn
2003-09-01
Medicinal Product no longer authorised 119 PATIENT ALERT CARD TEXT (NOT INCLUDED IN PACK OR AS PART OF THE PACKAGE LEAFLET) TRUDEXA PATIENT ALERT CARD This alert card contains important safety information that you need to be aware of before you are given Trudexa and during treatment with Trudexa. • Show this card to any doctor involved in your treatment. INFECTIONS Trudexa increases the risk of getting infections. Infections may progress more rapidly and be more severe. This includes tuberculosis. _Prior to Trudexa treatment:_ • You should not be treated with Trudexa if you have a severe infection. • You should be screened for tuberculosis. It is very important that you tell your doctor if you have ever had tuberculosis, or if you have been in close contact with someone who has had tuberculosis. Please record the dates of the last screening for tuberculosis below: Tuberculin test: _______________ Chest X-ray: _______________ _During Trudexa treatment: _ • If you develop symptoms suggestive of infections, such as fever, persistent cough, weight loss, or listlessness, seek medical attention immediately. HEART FAILURE _Prior to Trudexa treatment: _ • Trudexa should not be used if you have moderate to severe heart failure. _During Trudexa treatment: _ • If you develop symptoms of heart failure (shortness of breath or swelling of the feet) seek medical attention immediately. DATES OF TRUDEXA TREATMENT: 1 st injection: _______________________ Following injections: _______________________ _______________________ _______________________ _______________________ • See the Trudexa package leaflet for more information. • Please make sure you also have a list of all your other medicines with you at any visit to a health care professional. Patient’s Name: _____________________ Doctor’s Name: _____________________ Doctor’s Phone: _____________________ • Keep this card with you for 5 months after the last Trudexa dose, since side effects may occur a long time after your last dose of Trudexa. Medicinal Pro Przeczytaj cały dokument
Medicinal Product no longer authorised 1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Medicinal Product no longer authorised 2 1. NAME OF THE MEDICINAL PRODUCT Trudexa 40 mg solution for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 0.8 ml single dose vial contains 40 mg of adalimumab. Adalimumab is a recombinant human monoclonal antibody expressed in Chinese Hamster Ovary cells. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Rheumatoid arthritis Trudexa in combination with methotrexate, is indicated for: the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Trudexa can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Trudexa has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. Psoriatic arthritis Trudexa is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. Ankylosing spondylitis Trudexa is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. Crohn’s disease Trudexa is indicated for treatment of severe, active Crohn’s disease, in patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. For induction treatment, Trudexa should be given in combination with cortiocosteroids. Trudexa can be given as monoth Przeczytaj cały dokument